Franziska Fries
About
Franziska Fries studied pharmacy at Saarland University in Saarbrücken, where she was awarded the Deutschlandstipendium for her outstanding academic achievements. In 2020, she completed her master's thesis in the Microbial Natural Products department of Prof. Dr. Müller, working on the establishment of a Staphylococcus aureus infection model in zebrafish larvae to investigate new potential active compounds in vivo at an early stage.
After successful licensure as a pharmacist in 2021, Franziska returned to HIPS and continues her work as a PhD student. Franziska’s research focuses on target identification and mode-of-action studies of novel antimicrobial natural products as well as the investigation of their ADME-Tox properties using zebrafish larvae.
2024
Point mutations in the ygiV promoter region lead to cystobactamid resistance and reduced virulence in E. coli
Müller R, Risch T, Kolling D, Mostert D, Seedorf T, Heimann D, Kohnhäuser D, Deschner F, Fries F, Solga D, …, Herrmann J, Sieber S (2024)
BookDOI: 10.21203/rs.3.rs-3751821/v1
The Peptide Antibiotic Corramycin Adopts a β-Hairpin-like Structure and Is Inactivated by the Kinase ComG
Adam S, Fries F, Tesmar A, Rasheed S, Deckarm S, Sousa C, Reberšek R, Risch T, Mancini S, Herrmann J, …, Kalinina O, Müller R (2024)
J. Am. Chem. Soc.DOI: 10.1021/jacs.3c13208
2023
Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin a Using a Staphylococcus aureus Infection Model in Zebrafish Embryos
Fries F, Kany A, Rasheed S, Hirsch A, Müller R, Herrmann J (2023)
International journal of molecular sciences 24 (16)DOI: 10.3390/ijms241612791
2021
Zebrafish: An Attractive Model to Study Staphylococcus aureus Infection and Its Use as a Drug Discovery Tool
Rasheed S, Fries F, Müller R, Herrmann J (2021)
Pharmaceuticals 14 (6)DOI: 10.3390/ph14060594